NCT02699073View on ClinicalTrials.gov

Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

July 9, 2018

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

regorafenib

"160mg once daily during 3 weeks followed by 1 week off therapy.~Regorafenib will be taken until disease progression according to the CHOI and RECIST1.1 criteria, death or inacceptable toxicity."

Trial Locations (8)

Unknown

CHU Jean Minjoz, Besançon

Hôpitlal Henri Mondor, Créteil

Institut Hospitalier Franco-Britannique, Levallois-Perret

CHRU Claude Huriez, Lille

ICM Val D'Aurelle, Montpellier

Hôpital Pitié Salpêtrière, Paris

Hôpital Saint Antoine, Paris

Insitut Mutualiste Montouris, Paris

All Listed Sponsors
lead

GERCOR - Multidisciplinary Oncology Cooperative Group

OTHER

NCT02699073 - Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib | Biotech Hunter | Biotech Hunter